Travere Therapeutics
TVTX
197 hedge funds and large institutions have $1.66B invested in Travere Therapeutics in 2024 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 74 increasing their positions, 53 reducing their positions, and 28 closing their positions.
71% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 28
43% more capital invested
Capital invested by funds: $1.16B → $1.66B (+$499M)
40% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 53
39% more call options, than puts
Call options by funds: $22.6M | Put options by funds: $16.2M
11% more funds holding
Funds holding: 178 → 197 (+19)
2.55% more ownership
Funds ownership: 108.2% → 110.75% (+2.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$71.2M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$51.3M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$33.7M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
+$21.4M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$20.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$39.4M |
| 2 |
FC
Finepoint Capital
Boston,
Massachusetts
|
-$24.9M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$18M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$14.9M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$7.96M |
TVTX Hedge Fund Activity: Q4 2024 in Review
197 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q4 2024, worth a combined $1.66B — up 43% from $1.16B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new TVTX positions and 28 closed out — a net gain of 20 holders — while 74 added to existing stakes and 53 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $71.2M. The largest seller was Woodline Partners, cutting an estimated $39.4M.
- 197 institutional investors held Travere Therapeutics (TVTX) as of Q4 2024, up from 178 in Q3 2024.
- Funds reported $1.66B of Travere Therapeutics stock for Q4 2024, up 43% quarter-over-quarter.
- 48 funds opened new Travere Therapeutics positions in Q4 2024 and 28 closed out, a net change of +20 holders.
- The largest Travere Therapeutics buyer in Q4 2024 was Janus Henderson Group, an estimated $71.2M added.
- The largest Travere Therapeutics seller in Q4 2024 was Woodline Partners, an estimated $39.4M sold.
Based on aggregated 13F filings for Q4 2024.